Genetic Technologies Limited (GENE)

Market Cap	6.86M
Revenue (ttm)	5.78M
Net Income (ttm)	-8.67M
Shares Out	4.57M
EPS (ttm)	-3.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,270
Open	1.440
Previous Close	1.480
Day's Range	1.440 - 1.500
52-Week Range	1.380 - 4.750
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2024

About GENE

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Employees: 60
• Stock Exchange: NASDAQ
• Ticker Symbol: GENE

Financial Performance

In 2023, GENE's revenue was 8.69 million, an increase of 27.83% compared to the previous year's 6.79 million. Losses were -11.75 million, 64.8% more than in 2022.

Financial numbers in AUD